The Most Comprehensive Clinical Research Exome, with a Flexible Workflow

The SureSelect platform provides a flexible workflow with different library prep options for your diverse needs. Our highly proven SureSelectXT library prep with mechanical shearing provides a very robust solution for highly accurate results. For labs with enzymatic shearing needs or a need for faster turnaround time, the SureSelectQXT library prep offers the solution with a 90-minute hybridization, with comparable performance to SureSelectXT.




Confidence Where it Matters

The SureSelect Clinical Research Exome V2 utilizes the SureSelect Human All Exon V6 as its core design with boosted coverage in disease-associated regions, enabling more comprehensive coverage of highly curated databases (Table 1) and facilitating more confident variant calling within these targets. This design consists of targets included in databases such as the Online Mendelian Inheritance in Man (OMIM), the Human Genome Mutation Database (HGMD) and NCBI’s ClinVar, along with additional targets to disease-relevant regions as defined by Emory University and the Children’s Hospital of Philadelphia.



SureSelect Clinical Research Exome V2 Has Superior Content…That Matters!

The CRE V2 enables better gene coverage in more difficult exonic regions, typically left out of designs due to high GC content and problematic sequencing. Also, researchers are able to detect more pathogenic ClinVar variants when compared with using competitor exomes.


Figure 3.
Comparison of the SureSelect Clinical Research Exome V2 vs competitor exomes, using their respective design .bed files. Both tables show significantly more unique exonic regions and Pathogenic/Likely Pathogenic variants found in Clinical Research Exome V2 when compared to Competitor IL, Competitor R, and Competitor I.


Frequently Asked Questions

What differentiates CRE V2 from V1?

Based on analysis from Emory University and the Children’s Hospital of Philadelphia, the CRE V2 is comprised of the SureSelect Human All Exon V6, as well as enhanced coverage of an additional 1,099 disease-associated genes; in excess of 75,000 splice sites of non-coding exons; more than 12,000 previously reported deep intronic variants; over 800 previously reported variants in promoter regions, and non-coding RNAs. 71 breakpoint spanning probes have also been included for common deletions. The 67.3 Mb CRE V2 design enables deeper reach into regions of the genome not previously accessible through standard WES.

What are the disease-associated targets and how are they defined?

Disease-associated targets are genes linked to disorders. These were identified through the gene curation effort led by Emory University and CHOP, with data aggregated through large-scale literature and database curation efforts, deep sequencing of genes, functional validation of disease causality of gene variants through cDNA sequencing and breakpoint sequencing of variants.

When should I use CRE V2 instead of V6?

With its optimized bait selection and the newest curated disease-associated content, CRE V2 focuses additional sequencing power where it matters most, providing the most comprehensive coverage of clinical targets.

Which library prep solutions are CRE V2 compatible with?

The Clinical Research Exome V2 is compatible with best in class SureSelect library prep options (XT, XT2, and QXT).